These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39093590)

  • 21. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
    Ruan Z; Yang L; Shi H; Yue X; Wang Y; Liang M; Hu H
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):221-233. PubMed ID: 33317348
    [No Abstract]   [Full Text] [Related]  

  • 22. Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
    Blakely KK; Weaver K
    Nurs Womens Health; 2020 Oct; 24(5):370-376. PubMed ID: 32890462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 24. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
    Slawson DC
    Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of semaglutide versus liraglutide in clinical practice.
    Goncalves E; Bell DS
    Diabetes Metab; 2020 Nov; 46(6):515-517. PubMed ID: 31606525
    [No Abstract]   [Full Text] [Related]  

  • 27. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
    Hu S; Shi C; Ma Y; Wang S; Gu S; Qi C; Fan G
    Diabetes Obes Metab; 2024 Aug; 26(8):3176-3190. PubMed ID: 38738340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pursuit of optimal semaglutide dosing in type 2 diabetes continues.
    Sherrill CH; Hwang AY
    Lancet; 2023 Aug; 402(10403):668-669. PubMed ID: 37385277
    [No Abstract]   [Full Text] [Related]  

  • 30. Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.
    Martínez-Montoro JI; Picón-César MJ; Generoso-Piñar M; Fernández-Valero A; López-Montalbán Á; Simón-Frapolli VJ; Hernández-Bayo J; Pinzón-Martín JL; Tinahones FJ
    J Intern Med; 2024 Jan; 295(1):113-115. PubMed ID: 37902577
    [No Abstract]   [Full Text] [Related]  

  • 31. Semaglutide: new dawn for diabetics.
    Memon A; Tehrim M; Kumari B
    J Pak Med Assoc; 2023 Mar; 73(3):721. PubMed ID: 36932797
    [No Abstract]   [Full Text] [Related]  

  • 32. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
    Kalra S; Kalhan A; Berard L
    Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
    [No Abstract]   [Full Text] [Related]  

  • 33. Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
    Basolo A; Fierabracci P; Salvetti G; Santini F
    J Endocrinol Invest; 2024 May; 47(5):1047-1049. PubMed ID: 38157134
    [No Abstract]   [Full Text] [Related]  

  • 34. Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.
    Barrett A; Debackere N; Ribeiro A; Keapoletswe K; Zingel R; Coles B
    Adv Ther; 2023 Aug; 40(8):3446-3464. PubMed ID: 37286889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fathoming the Role of Semaglutide in Obesity Therapeutics.
    George M; Balachandran K; Jinson J
    Clin Ther; 2023 Aug; 45(8):804-805. PubMed ID: 37442659
    [No Abstract]   [Full Text] [Related]  

  • 36. The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.
    Heile M; Taddei-Allen P
    Am J Manag Care; 2020 Dec; 26(16 Suppl):S323-S324. PubMed ID: 33439580
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
    Ericsson Å; Fridhammar A
    J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
    Phizackerley D
    BMJ; 2024 Jan; 384():q53. PubMed ID: 38224977
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.